Steven Cohen Inhibrx, Inc. Transaction History

Point72 Asset Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $1.36 Million - $2.24 Million	80,381 Added 33.62%	319,500 $8.29 Million
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $9.47 Million - $13.9 Million	-513,381 Reduced 68.22%	239,119 $4.51 Million
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $5.96 Million - $9.85 Million	295,400 Added 64.62%	752,500 $18.5 Million
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $2.8 Million - $5.98 Million	-242,000 Reduced 34.62%	457,100 $8.21 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $5.96 Million - $17.7 Million	699,100 New	699,100 $7.94 Million

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $565M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.